Patents Assigned to St. Luke's-Roosevelt Hospital Center
  • Cell culture models for validating candidate compounds for use in treating COPD and other diseases
    Patent number: 9885727
    Abstract: The present invention relates to methods of diagnosing, monitoring, and treating elastin fiber injuries. In additional preferred embodiments, the present invention relates to methods of validating candidate compounds for use in treating chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, refractory asthma, and other related diseases. Examples of such methods include determining if the candidate compound decreases the degradation of elastic fiber in a patient administered the candidate compound by measuring, using mass spectrometry employing an internal standard, a marker of elastic fiber degradation in a sample of a body fluid or a tissue of the patient. The invention provides that a decrease in the presence of the marker compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: February 6, 2018
    Assignees: St. Luke's-Roosevelt Hospital Center, The Trustees of Columbia University in the City of New York
    Inventors: Gerard M Turino, Shuren Ma, Yong Y Lin, Seymour Leiberman
  • Methods of validating candidate compounds for use in treating COPD and other diseases
    Patent number: 9068942
    Abstract: The present invention relates to methods of diagnosing, monitoring, and treating elastin fiber injuries. In additional preferred embodiments, the present invention relates to methods of validating candidate compounds for use in treating chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, refractory asthma, and other related diseases. Examples of such methods include determining if the candidate compound decreases the degradation of elastic fiber in a patient administered the candidate compound by measuring, using mass spectrometry employing an internal standard, a marker of elastic fiber degradation in a sample of a body fluid or a tissue of the patient. The invention provides that a decrease in the presence of the marker compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: June 30, 2015
    Assignees: The Trustees of Columbia University in the City of New York, St. Luke's-Roosevelt Hospital Center
    Inventors: Gerard M Turino, Shuren Ma, Yong Y Lin, Seymour Leiberman
  • Method for estimating creatinine clearance using measurements of body cell mass
    Patent number: 5722396
    Abstract: Creatinine clearance is estimated in a patient by determining his or her body cell mass. In turn, the body cell mass of the patient is measured using bioimpedance analysis techniques. The determined value of body cell mass is normalized by the height.sup.2 of the patient. The body cell mass or its normalized value provides an indication of actual creatinine clearance in the subject through use of a predictive formula. From this prediction, accurate dosages of potentially nephrotoxic medications can be appropriately prescribed.
    Type: Grant
    Filed: August 13, 1996
    Date of Patent: March 3, 1998
    Assignee: St. Luke's-Roosevelt Hospital Center
    Inventors: Donald P. Kotler, Emilia M. Sordillo